Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: implications for peptide vaccines.

@article{Brinckerhoff1999TerminalMI,
  title={Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: implications for peptide vaccines.},
  author={Laurence H Brinckerhoff and Vladimir V. Kalashnikov and Lee W Thompson and Galina V. Yamshchikov and Richard A. Pierce and Holly Galavotti and Victor H Engelhard and Craig L Slingluff},
  journal={International journal of cancer},
  year={1999},
  volume={83 3},
  pages={326-34}
}
Peptide epitopes for tumor-reactive cytotoxic T-lymphocytes (CTL) have been identified on human cancers and are being used in tumor vaccine trials. However, the pharmacokinetics and pharmacodynamics of such peptides have been inadequately studied. It is predicted that immunogenic tumor peptides would have short half-lives in vivo. The goal of the present work was to evaluate the stability of the immunogenic peptide MART-1(27-35) in fresh normal human plasma (NHP) and to identify modifications… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 41 extracted citations

Multisite aggregation of p53 and implications for drug rescue.

Proceedings of the National Academy of Sciences of the United States of America • 2017
View 1 Excerpt

Similar Papers

Loading similar papers…